Cerebrolysin
European-approved neurotrophic peptide mixture — enhances BDNF/NGF, approved for Alzheimer's and stroke in 50+ countries.
Research facts
| Half-life | Variable (mixture) |
|---|---|
| Route | IV / IM |
| Typical dose | 5–30 mL/day IV infusion |
| Frequency | Daily infusions over 5–10 day cycles |
| Solvent | Commercial IV formulation |
| pH | N/A |
| Stability | Refrigerated |
Mechanism of action
Cerebrolysin is a standardised peptide preparation derived from porcine brain protein by enzymatic proteolysis, yielding a mixture of neurotrophic peptides and amino acids (predominantly low-molecular weight peptides). Its primary mechanism involves NGF-like and BDNF-like effects on neuronal survival, differentiation, and synaptic plasticity. It also exhibits direct neuroprotective effects against excitotoxicity and ischaemia, modulates APP processing (reducing amyloid formation), and reduces tau phosphorylation. Approved in Germany, Austria, China, Russia, and 50+ other countries for Alzheimer's disease, vascular dementia, and stroke rehabilitation.
Documented effects (research-model)
- Approved in 50+ countries for Alzheimer's and stroke rehabilitation
- Multiple RCT meta-analyses showing cognitive benefit in dementia
- BDNF and NGF mimetic effects without systemic neurotrophic toxicity
- Synaptic plasticity enhancement
- Neuroprotection in acute stroke (established clinical use)
- Potential in traumatic brain injury and mild cognitive impairment
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Clinical (Europe) | 10–30 mL IV infusion | Daily × 10–20 days (then cycle off) | 10–20 day cycles, 1–4× per year | Cerebrolysin 5mL/10mL ampoules |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- Semax MODERATE
Cerebrolysin provides broad neurotrophic support; Semax upregulates BDNF specifically. Combined neurotrophin elevation for cognitive enhancement.
Myths & misconceptions
Evidence gaps
- Not FDA or EMA approved — primarily European and Asian clinical use.
- Active ingredient identification is incomplete — mixture with variability.
- Head-to-head comparison with cholinesterase inhibitors lacking.
Safety notes
Generally well-tolerated. Requires IV administration (medical supervision). Rare: hypersensitivity reactions, CNS excitability at high doses. Contraindicated in severe renal impairment and epilepsy. IV use requires trained personnel.
Biomarkers to monitor
Primary-source citations
- PMID 34587684 — Cerebrolysin for Alzheimer's disease: a systematic review (Cochrane Database Syst Rev. 2021)
Frequently asked
What is Cerebrolysin?
Cerebrolysin (FPF-1070 — Brain-Derived Peptide Mixture) is a research compound classified in our library as Tier B — Some human data + strong preclinical evidence.. European-approved neurotrophic peptide mixture — enhances BDNF/NGF, approved for Alzheimer's and stroke in 50+ countries.
What is the evidence tier for Cerebrolysin?
We classify Cerebrolysin as Tier B: Some human data + strong preclinical evidence. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of Cerebrolysin?
For Cerebrolysin, typical research dose is 5–30 mL/day IV infusion, route is IV / IM, half-life is Variable (mixture). Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
Is Cerebrolysin safe?
Generally well-tolerated. Requires IV administration (medical supervision). Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.